(Fig. 6) Studies have confirmed that low-dose STING agonists, such as cGAMP and ADU-S100, can be used as a method to mediate tumor immunity.534 In a Lewis lung cancer model, intra-tumoral injection of ADU-S100 promoted VN, modulating the tumor immune microenvironment, and increasing CD8+ T cell infiltration, controlling tumor growth.535 Additionally, ADU-S100 administration induced the secretion of cytokines and chemokines, including LTα, LTβ, LIGHT, CCL19, and CCL21, as well as the anti-angiogenic factors Tnfsf15 and Cxcl10, in a mouse melanoma model. This evidence concerns the gene STING1 and neoplasm.